In the era of precision medicine, predictive biomarkers, such as genomic alterations for targeted therapy36 and PD-L1 expression and tumor mutation burden for immunotherapy8,37, are playing an increasingly important role to guide selection of therapeutic strategies. This evidence concerns the gene CD274 and neoplasm.